TRAILR1/TNFRSF10A Antibody (32A242) - BSA Free

Cells undergo programmed cell death (Apoptosis) in response to various stimuli. Apoptosis is essential for morphogenesis, tissue homeostasis, and host defense. Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel death domain containing receptor was recently identified and designated DR4 (for death receptor 4). The ligand for this novel death receptor has been identified and termed TRAIL, which is a new member in the TNF family. DR4 is also called TRAIL receptor-1 (TRAIL-R1). DR4 is expressed in most human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4 mediates apoptosis and NF-kB activation in many tissues and cells.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 3 applications: IB, ICC/IF, WB.

Showing Publications 1 - 8 of 8.

Publications using NB100-56528	Applications	Species
Lee SR, Quan KT, Byun HS et al. Accelerated degradation of cFLIPL and sensitization of the TRAIL DISC-mediated apoptotic cascade by pinoresinol, a lignan isolated from Rubia philippinensis Sci Rep 2019-09-18 [PMID: 31534206] (IB, Human)	IB	Human
Wen Q, Wang W, Luo J et al. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway. Oncotarget. 2016-03-30 [PMID: 27050281] (WB, Human)	WB	Human
Di X, Zhang G, Zhang Y et al. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Oncotarget 2013-09-01 [PMID: 23988408] (ICC/IF)	ICC/IF
Brooks AD, Jacobsen KM, Li W et al. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res. 2010-05-01 [PMID: 20442297]
Laguinge LM, Samara RN, Wang W et al. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Res. 2008-02-01 [PMID: 18245494] Details: WB [human colerectal cancer (CRC) cells], Fig. 4A.
Xu J, Zhou JY, Wu GS. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res. 2006-10-15 [PMID: 17047073]
Cisternas P, Moreno RD. Comparative analysis of apoptotic pathways in rat, mouse, and hamster spermatozoa. Mol Reprod Dev. 2006-10-01 [PMID: 16868928] (WB) Details: DR4/TRAILR1 (NT) (IMG-275). WB: Mouse, rat, and hamster spermatozoa, Fig 3A. Note: The DR4/TRAIL1 antibody was detected in mouse and rat spermatozoa but not in hamster, Fig 3A.	WB
Jin F, Liu X, Zhou Z et al. Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res. 2005-07-15 [PMID: 16024638] (WB) Details: IMGENEX antibodies cited for WB: 1. Caspase-3 mAb, clone 31A1067 (IMG-144A): Fig 3C, DU145 prostate adenocarcinoma cells. 2. DcR1 pAb (IMG-245-1/IMG-245-2): Fig 6C, DcR1 overexpressing DU145 cells. Note: The specificity of the DcR1 pAb was validated in Dc	WB

Array NB100-56528

• TRAILR1/TNFRSF10A Antibodies
• TRAILR1/TNFRSF10A Antibody Pair
• TRAILR1/TNFRSF10A ELISA Kit
• TRAILR1/TNFRSF10A Proteins
• TRAILR1/TNFRSF10A Proteins and Enzymes